Dogra Gupta. The SARS-CoV-2 strain (NIV-2020-770) used in developing the BBV152 vaccine is retrieved from tourists who arrive in New Delhi, India. The scientific...
28 KB (1,980 words) - 13:25, 6 October 2024
000 participants. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19. Peer-reviewed results published...
17 KB (1,214 words) - 12:47, 25 August 2024
- University of Oxford’s AZD1222 (marketed as Covishield in India) and BBV152 (marketed as Covaxin, developed in India by Bharat Biotech in association...
5 KB (335 words) - 21:24, 16 April 2024
Biotech/Indian Council of Medical Research Completed Bharat Biotech's Covaxin (BBV152) is an inactivated COVID-19 vaccine that uses adjuvant Alhydroxiquim-II...
143 KB (4,780 words) - 19:35, 15 October 2024
the Serum Institute of India (SII) under the trade name "Covishield", and BBV152 (Covaxin), a vaccine developed by Bharat Biotech in association with the...
337 KB (26,345 words) - 23:53, 10 September 2024
doi:10.1038/s41573-021-00163-y. PMC 8023785. PMID 33824489. "COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine". www.who.int. Retrieved 2024-07-14. Soni...
38 KB (4,235 words) - 12:27, 3 September 2024
world, and their joint product was mostly referred to simply as 'Pfizer'. BBV152 CureVac Moderna COVID-19 vaccine Novavax COVID-19 vaccine Oxford–AstraZeneca...
41 KB (3,732 words) - 00:41, 14 October 2024
2021). "Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees". Clinical Infectious Diseases. 74 (ciab411). Oxford University...
225 KB (21,555 words) - 04:23, 7 October 2024
Federal Audit Court and the Federal Public Prosecutor's Office. Covaxin (or BBV152) is a vaccine against COVID-19 produced in India by the Bharat Biotech laboratory...
15 KB (1,189 words) - 21:09, 28 August 2024
January, the DCGI also granted an interim emergency use authorisation to BBV152 (trade name "Covaxin"), a domestic vaccine developed by Bharat Biotech in...
181 KB (11,351 words) - 23:42, 5 August 2024
Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years | Ocugen, Inc". ir.ocugen.com. "COVID-19 Vaccinations...
134 KB (10,719 words) - 18:27, 9 October 2024
convalescent sera of the COVID-19 cases and recipients of Bharat Biotech's BBV152 (Covaxin) were able to neutralise VUI B.1.617 although with a lower efficacy...
130 KB (12,297 words) - 20:50, 10 September 2024
It has a shelf life of at least six months. Covaxin On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
12 KB (820 words) - 23:37, 24 September 2024
Tripti; Coshic, Poonam (July 2022). "Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants...
6 KB (603 words) - 15:42, 12 August 2024
Adenovirus that causes cold in Chimpanzees. Covaxin On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
34 KB (1,462 words) - 16:25, 3 March 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
289 KB (22,003 words) - 23:57, 24 September 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
30 KB (2,679 words) - 09:44, 22 April 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
26 KB (3,147 words) - 02:36, 13 October 2023
safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"...
95 KB (18,965 words) - 23:35, 15 September 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
33 KB (2,912 words) - 02:41, 17 February 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
31 KB (2,656 words) - 03:53, 3 January 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
34 KB (3,831 words) - 09:07, 1 October 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
23 KB (2,651 words) - 13:22, 3 August 2023
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
30 KB (2,958 words) - 05:32, 27 July 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
28 KB (2,808 words) - 05:39, 28 July 2024
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
24 KB (2,847 words) - 21:00, 16 October 2023
vaccine was despatched from the Serum Institute of India. On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech...
23 KB (2,699 words) - 02:57, 13 October 2023
learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys"...
24 KB (1,967 words) - 09:44, 11 July 2024